The botulinum toxin as a therapeutic agent: molecular and pharmacological insights

References

• Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000;80:715–760.
   Web of Science ®Google Scholar
• Singh BR. Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting. Neurotox Res. 2006;209:73–92.
   Google Scholar
• Erbguth FJ, Nauman M. Historical aspects of botulinum toxin: Justinus Kerner (1786–1862) and the “sausage poison”. Neurology. 1999;53:1850–1853.
   Google Scholar
• Ting PT, Freiman A. The story of Clostridium botulinum: from food poisoning to Botox. Clin Med. 2004;4:258–262.
   PubMed Web of Science ®Google Scholar
• van Ermengem E. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. Rev Infect Dis. 1979;1:701–719.
   PubMedGoogle Scholar
• Cherington M. Clinical spectrum of botulism. Muscle Nerve. 1998;21:701–710.
   PubMed Web of Science ®Google Scholar
• Snipe PT, Sommer H. Studies on botulinus toxin: 3. Acid precipitation of botulinus toxin. J Infect Dis. 1928;43:152–160.
   Google Scholar
• Stefanye D, Schantz EJ, Spero L. Amino acid composition of crystalline botulinum toxin, type A. J Bacteriol. 1967;94:277–278.
   Web of Science ®Google Scholar
• Lamanna C, Spero L, Schantz EJ. Dependence of time to death on molecular size of botulinum toxin. Infect Immun. 1970;1:423–424.
   PubMedGoogle Scholar
• Schantz EJ. Some chemical and physical properties of Clostridium botulinum toxins in culture. Jpn J Microbiol. 1967;11:380–383.
   Google Scholar
• Scott AB, Rosenbaum A, Collins CC. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973;12:924–927.
   PubMedGoogle Scholar
• Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology. 1980;87:1044–1049.
   PubMed Web of Science ®Google Scholar
• Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins. 2012;4:913–939.
   PubMed Web of Science ®Google Scholar
• Carruthers J, Stubbs HA. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. Can J Neurol Sci. 1987;14(1):42–45.
   Web of Science ®Google Scholar
• Lorenc ZP, Kenkel JM, Fsgien S, et al. IncobotulinumtoxinA: background, mechanism of action and manufacturing. Aesthet Surg J. 2013;33:18S–22S.
   Web of Science ®Google Scholar
• Kane M, Donofrio L, Ascher B, et al. Expanding the use of neurotoxins in facial aesthetics: a consensus panels’ assessment and recommendations. J Drugs Dermatol. 2010;9(Suppl):S7–S22.
   Google Scholar
• Sattler G. Current and future botulinum neurotoxin typa A preparations in aesthetics: a literature review. J Drugs Dermatol. 2010;9:1065–1071.
   Web of Science ®Google Scholar
• Humeau Y, Dossau F, Grant NJ, Poulain B. How botulinum and tetanus neurotoxins block neurotransmitter release? Biochimie. 2000;82:427–446.
   PubMed Web of Science ®Google Scholar
• Inoue K, Fujinaga Y, Watanabe T, et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun. 1996;64:1589–1594.
   PubMed Web of Science ®Google Scholar
• Klein AW. Complications and adverse reactions with the use of botulinum toxin. Dis Mon. 2002;48:336–356.
   Web of Science ®Google Scholar
• Gu S, Rumpel S, Zhou J, et al. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science. 2012;335:977–981.
   PubMed Web of Science ®Google Scholar
• Fujinaga Y, Inoue K, Watarai S, et al. Molecular characterization of binding subcomponents of Clostridium botulinum type C progenitor toxin for intestinal epithelial cells and erythrocytes. Microbiology. 2004;150:1529–1538.
   PubMed Web of Science ®Google Scholar
• Matsumura T, Sugawara Y, Yutani M, et al. Botulinum toxin A complex exploits intestinal M cells to enter the host and exert neurotoxicity. Nat Commun. 2015;6:6255.
   Web of Science ®Google Scholar
• Grein S, Mander GJ, Fink K. Stability of botulinum neurotoxin type A, devoid of complexing proteins. Botulinum J. 2011;2:49–58.
   Google Scholar
• Eisele KH, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 2011;57:555–565.
   Web of Science ®Google Scholar
• Montecucco C, Papini C, Schiavo G. Bacterial toxins penetrate cells via a four-step mechanism. FEBS Lett. 1994;346(1):92–98.
   PubMed Web of Science ®Google Scholar
• Nishiki T, Kamata Y, Nemoto Y, et al. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem. 1994;269:10498–10503.
   PubMed Web of Science ®Google Scholar
• Rummel A, Mahrhold S, Bigalke H, Binz T. The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction. Mol Microbiol. 2004;51:631–643.
   PubMed Web of Science ®Google Scholar
• Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006;312(5773):595–596.
   Web of Science ®Google Scholar
• Mahrhold S, Strotmeier J, Garcia-Rodriguez C, et al. Identification of the SV2 protein receptor-binding site of botulinum neurotoxin type E. Biochem J. 2013;453:37–47.
   Web of Science ®Google Scholar
• Nishiki T, Tokuyama Y, Kamata Y, et al. The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a. FEBS Lett. 1996;378:253–257.
   PubMed Web of Science ®Google Scholar
• Rummel A, Eichner T, Weil T, et al. Identification of the receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc Natl Acad Sci U S A. 2007;104:359–364.
   PubMed Web of Science ®Google Scholar
• Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem. 2010;79:591–617.
   PubMed Web of Science ®Google Scholar
• de Paiva A, Meunier FA, Molgo J, Aoki KR, Dolly JO. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A. 1999;96:3200–3205.
   PubMed Web of Science ®Google Scholar
• Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29:1761–1768.
   PubMed Web of Science ®Google Scholar
• Frevert J. Pharmaceutical, biological and clinical properties of botulinum neurotoxin type A products. Drugs R D. 2015;15(1):1–9.
   PubMed Web of Science ®Google Scholar
• Berry MG, Stanek JJ. Botulinum neurotoxin A: a review. J Plast Reconstr Aesthet Surg. 2012;65:1283–1291.
   Web of Science ®Google Scholar
• Wheeler A, Smith HS. Botulinum toxins: mechanism of action, antinociception and clinical applications. Toxicology. 2013;306:124–146.
   PubMed Web of Science ®Google Scholar
• Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med. 1994;87:719.
   PubMed Web of Science ®Google Scholar
• Dressler D. Clinical applications of botulinum toxin. Curr Opinon Microbiol. 2012;15:325–336.
   PubMed Web of Science ®Google Scholar
• Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or hindrance. Biologics. 2010;4:325–332.
   PubMedGoogle Scholar
• Dressler D. Clinical presentation and management of antibody induced failure of botulinum toxin therapy. Mov Disord. 2004;19(Suppl 8):S92–S100.
   PubMed Web of Science ®Google Scholar
• Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9:213–217.
   PubMed Web of Science ®Google Scholar
• Jankovic J. Botulinum toxin: clinical implications of antigenicity and immunoresistance. In: Brin MF, Jankovic J, Hallett M, editors. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:409–415.
   Google Scholar
• Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin cervical dystonia. Neurology. 2003;60:1186–1188.
   PubMed Web of Science ®Google Scholar
• Dressler D. New formulation of Botox: complete antibody-induced therapy failure in hemifacial spasm. J Neurol. 2004;251(3):360.
   Web of Science ®Google Scholar
• Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs. 2007;67:669–683.
   PubMed Web of Science ®Google Scholar
• Dressler D. Five-year experience with incobotulinumtoxinA (Xeomin(R)): the first botulinum toxin drug free of complexing proteins. Eur J Neurol. 2012;19:385–389.
   PubMed Web of Science ®Google Scholar
• Bakheit AM. The possible adverse effects of intramuscular botulinum toxin injections and their management. Curr Drug Saf. 2006;1:271–279.
   PubMedGoogle Scholar
• Tintner R, Gross R, Winzer UF, Smalky KA, Jankovic J. Autonomic function after botulinum toxin type A or B: a double-blind, randomized trial. Neurology. 2005;65:765–767.
   Web of Science ®Google Scholar
• De Almeida AT, De Boulle K. Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications. J Cosmet Laser Ther. 2007;9(Suppl 1):17–22.
   Google Scholar
• Trindade de Almeida AR, Marques E, de Almeida J, Cunha T, Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg. 2007;33:S37–S43.
   PubMed Web of Science ®Google Scholar
• Hexsel D, Dal’Forno T, Hexsel C, Do Prado DZ, Lima MM. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg. 2008;34:52–59.
   PubMed Web of Science ®Google Scholar
• Dodd SL, Rowell BA, Vrabas IS, Arrowsmith RJ, Weatherill PJ. A comparison of the spread of three formulations of botulinum neurotoxin A as determined by effects on muscle function. Eur J Neurol. 1998;5:181–186.
   Web of Science ®Google Scholar
• Carruthers A. Problems with toxins. Body Lang. 2010;35:43–44.
   Google Scholar
• Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE. Distant effects of local injection of botulinum toxin. Muscle Nerve. 1987;10:552–555.
   PubMed Web of Science ®Google Scholar
• Lange DJ, Rubin M, Greene PE, et al. Distant effects of locally injected botulinum toxin: a doubleblind study of single fiber EMG changes. Muscle Nerve. 1991;14:672–675.
   PubMed Web of Science ®Google Scholar
• Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol. 2003;49:34–38.
   PubMed Web of Science ®Google Scholar
• Antonucci F, Rossi C, Gianfranceschi L, Rossetto O, Caleo M. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008;28(14):3689–3696.
   PubMed Web of Science ®Google Scholar
• Restani L, Novelli E, Bottari D, et al. Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport. Traffic. 2012;13:1083–1089.
   PubMed Web of Science ®Google Scholar
• Mazzocchio R, Caleo M. More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system. Neuroscientist. 2015;21(1):44–61.
   PubMed Web of Science ®Google Scholar
• Restani L, Giribaldi F, Manich M, et al. Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog. 2012;8(12):1–19.
   Web of Science ®Google Scholar
• Bach-Rojecky L, Šalkovic-PetriŠic M, Lackovic Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol. 2010;633:10–14.
   PubMed Web of Science ®Google Scholar
• Wollmer MA, de Boer C, Kalak N, et al. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatry Res. 2012;46:574–581.
   PubMed Web of Science ®Google Scholar
• Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial. J Psychiatry Res. 2014;52:1–6.
   Web of Science ®Google Scholar
• Finzi E. The Face of Emotion: How Botox Affects Our Moods and Relationships. New York: Palgrave Macmillan; 2013.
   Google Scholar
• Magid M, Reichenberg JS, Poth PE, et al. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(8):837–844.
   PubMed Web of Science ®Google Scholar
• Davis JI, Senghas A, Brandt F, Ochsner KN. The effects of Botox injections on emotional experience. Emotion. 2010;10(3):433–440.
   PubMed Web of Science ®Google Scholar
• Neal DT, Chartrand TL. Embodied emotion perception: amplifying and dampening facial feedback modulates emotion perception accuracy. Soc Psychol Personal Sci. 2011;2(6):673–678.
   Web of Science ®Google Scholar
• Havas DA, Glenberg AM, Gutowski KA, Lucarelli MJ, Davidson RJ. Cosmetic use of botulinum toxin-A affects processing of emotional language. Psychol Sci. 2010;21(7):895–900.
   PubMed Web of Science ®Google Scholar
• Wang L, Sun Y, Yang W, Lindo P, Singh BR. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells. Toxicon. 2014;82:52–60.
   PubMed Web of Science ®Google Scholar
• Brandt F, O’Connell C, Cazzaniga A, Wagh JM. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. Dermatol Surg. 2010;36:2111–2118.
   Web of Science ®Google Scholar
• Foster KA, Chaddock JA. Targeted secretion inhibitors–innovative protein therapeutics. Toxins. 2010;2:2795–2815.
   PubMed Web of Science ®Google Scholar
• Masuyer G, Chaddock JA, Foster KA, Acharya KR. Engineered botulinum neurotoxins as new therapeutics. Annu Rev Pharmacol Toxicol. 2014;54:27–51.
   PubMed Web of Science ®Google Scholar
• Kukreja R, Singh BR.. Botulinum neurotoxins-structure and mechanism of action. In: Proft T, editor. Microbial Toxins: Current Research and Future Trends. Norfolk: Caister Academic Press; 2009:15–40.
   Google Scholar